BioAdaptives, Inc. (OTC: BDPT) has detailed the scientific strategy behind its Xcellara(TM) cellular wellness platform as the company prepares for the commercial launch of XcellaraHeart(TM) on August 1. The platform integrates a stem/progenitor cell mobilization base with tissue-specific ingredients designed to support the body's natural signaling pathways and direct those cells to targeted areas.
The Xcellara base formula is supported by a human randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating stem and progenitor cells after four weeks, with no adverse effects on more than twenty blood parameters. This base is the only dietary supplement with such clinical evidence, according to the company.
XcellaraHeart, the first commercial product from the platform, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives plans to expand the platform with additional formulas targeting joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.
The company will make the complete scientific evidence dossier for XcellaraHeart available at products.xcellara.com/science. This dossier separates the findings from BioAdaptives' human clinical research on the Xcellara base from published research on Tanshinone IIA and the company's rationale for combining the two.
For more information about BioAdaptives and its products, visit www.bioadaptives.com or products.xcellara.com.
The Xcellara platform represents a novel approach in the dietary supplement industry by combining clinically proven stem cell mobilization with targeted delivery. This strategy could have implications for consumers seeking natural ways to support cellular health and specific bodily functions. For business leaders, the development highlights the growing intersection of biotechnology and consumer wellness, potentially opening new markets for evidence-based supplements.
BioAdaptives' focus on clinical validation and targeted formulations may set a new standard in the industry, emphasizing the importance of scientific backing in product development. As the company rolls out additional formulas, it will be important to monitor consumer adoption and competitive responses.
